Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8652925rdf:typepubmed:Citationlld:pubmed
pubmed-article:8652925lifeskim:mentionsumls-concept:C0015402lld:lifeskim
pubmed-article:8652925lifeskim:mentionsumls-concept:C0279030lld:lifeskim
pubmed-article:8652925pubmed:issue1lld:pubmed
pubmed-article:8652925pubmed:dateCreated1996-7-26lld:pubmed
pubmed-article:8652925pubmed:abstractTextA 43-year-old man with chronic active hepatitis C was treated with interferon-beta (IFN-beta) at a dosage of 6 x 10(6) IU/day for a planned 6-week period. Ocular hyperemia, ophthalmalgia, and increased intraocular pressure in the right eye developed 20 days after the start of treatment. Intraocular pressure remained high, even after discontinuation of IFN therapy, laser therapy, and iridectomy. Two days later, the right eye was removed because perforation had occurred. The ocular symptoms that developed in this case were thought to have been caused and exacerbated by IFN administration.lld:pubmed
pubmed-article:8652925pubmed:languageenglld:pubmed
pubmed-article:8652925pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8652925pubmed:citationSubsetIMlld:pubmed
pubmed-article:8652925pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8652925pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8652925pubmed:statusMEDLINElld:pubmed
pubmed-article:8652925pubmed:monthJanlld:pubmed
pubmed-article:8652925pubmed:issn0918-2918lld:pubmed
pubmed-article:8652925pubmed:authorpubmed-author:ToddDDlld:pubmed
pubmed-article:8652925pubmed:authorpubmed-author:NagamoriSSlld:pubmed
pubmed-article:8652925pubmed:authorpubmed-author:KitaharaKKlld:pubmed
pubmed-article:8652925pubmed:authorpubmed-author:HasumuraSSlld:pubmed
pubmed-article:8652925pubmed:authorpubmed-author:KugaKKlld:pubmed
pubmed-article:8652925pubmed:issnTypePrintlld:pubmed
pubmed-article:8652925pubmed:volume35lld:pubmed
pubmed-article:8652925pubmed:ownerNLMlld:pubmed
pubmed-article:8652925pubmed:authorsCompleteYlld:pubmed
pubmed-article:8652925pubmed:pagination15-8lld:pubmed
pubmed-article:8652925pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:meshHeadingpubmed-meshheading:8652925-...lld:pubmed
pubmed-article:8652925pubmed:year1996lld:pubmed
pubmed-article:8652925pubmed:articleTitleIntraocular hemorrhage developing during interferon therapy.lld:pubmed
pubmed-article:8652925pubmed:affiliationFirst Department of Internal Medicine, Jikei University School of Medicine, Tokyo.lld:pubmed
pubmed-article:8652925pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8652925pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8652925lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8652925lld:pubmed